Skip to main content
padlock icon - secure page this page is secure

Presence of urokinase plasminogen activator, its inhibitor and receptor in small cell lung cancer and non-small cell lung cancer

Buy Article:

$42.00 + tax (Refund Policy)

Spreading of cancer cells is dependent on the combined action of several proteolytic enzymes, such as serine proteases, comprising the urokinase pathway of plasminogen activation. Previous studies of lung cancer indicate that expression, localization and prognostic impact of the components of the plasminogen activation system differ in the different non-small cell lung cancer (NSCLC) types, whereas the expression of the components in small cell lung cancer (SCLC) has only sparingly been investigated. In the present study we investigate the presence of the components of the plasminogen activation system, and compare the levels of uPA, PAI-1 and uPAR in extracts of NSCLC-tissue and SCLC-tissue. A statistically significant difference, P = 0.037, was found between uPA-levels in NSCLC-patients (n = 75) and SCLC-patients (n = 8), the highest levels being found in NSCLC. No such difference was found for the two other components investigated, although a trend towards increased uPAR-levels was observed in SCLC, P = 0.055. The relationship between the levels of each of the components and other known clinical parameters was also analysed. No relationship was found between any of the components and the clinical parameters. This is the first report of a study using a quantitative method to compare levels of the components of the plasminogen activation system in tissue extracts from the two major lung cancer groups. The study shows that uPA, PAI-1 and uPAR are present in SCLC-tissue, suggesting that the plasminogen activation system could play a role in this type of cancer during invasion. In addition a difference in the levels of the components of the plasminogen activation system in NSCLC and SCLC is found, which could contribute to the differences in biology.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: RIGSHOSP, FINSEN LAB, DK-2100 COPENHAGEN, DENMARK. ODENSE UNIV HOSP, DEPT ONCOL, DK-5000 ODENSE, DENMARK. DANISH VET LAB, DEPT BIOCHEM & IMMUNOL, COPENHAGEN, DENMARK. FREDERIKSBERG UNIV HOSP, DEPT PATHOL, COPENHAGEN, DENMARK. RIGSHOSP, DEPT PATHOL, DK-2100 COPENHAGEN, DENMARK. 2: RIGSHOSP, FINSEN LAB, DK-2100 COPENHAGEN, DENMARK. ODENSE UNIV HOSP, DEPT ONCOL, DK-5000 ODENSE, DENMARK. DANISH VET LAB, DEPT BIOCHEM & IMMUNOL, COPENHAGEN, DENMARK. FREDERIKSBERG UNIV HOSP, DEPT PATHOL, COPENHAGEN, DENMARK. RIGSHOSP, DEPT PATHOL, DK-2100 COPENHAGEN, DENMARK. 3: RIGSHOSP, FINSEN LAB, DK-2100 COPENHAGEN, DENMARK. ODENSE UNIV HOSP, DEPT ONCOL, DK-5000 ODENSE, DENMARK. DANISH VET LAB, DEPT BIOCHEM & IMMUNOL, COPENHAGEN, DENMARK. FREDERIKSBERG UNIV HOSP, DEPT PATHOL, COPENHAGEN, DENMARK. RIGSHOSP, DEPT PATHOL, DK-2100 COPENHAGEN, DENMARK.

Publication date: January 1, 1997

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more